# Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

> **NCT04397770** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 40 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** SHR1210
- **DRUG:** apatinib mesylate
- **DRUG:** Temozolomide Injection

## Key facts

- **NCT ID:** NCT04397770
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05
- **Primary completion:** 2022-06
- **Final completion:** 2023-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04397770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04397770, "Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04397770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*